Search results
Results from the WOW.Com Content Network
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]
The study enrolled 34 patients, 28 of which underwent surgery to resect the PDAC. 19 of the patients who had undergone surgery then received atezolizumab, an immune checkpoint inhibitor. 16 of the patients on atezolizumab then received autogene cevumeran. 1 patient was considered to have insufficiently many neoantigens to manufacture the vaccine.
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Atezolizumab. PubMed provides review articles from the past five years (limit to free review articles)
Kohavision (shortened to KTV, previously also Koha Vision) is a Kosovan free-to-air television channel launched on September 21, 2000. [2] It was founded by politician and journalist Veton Surroi as part of KOHA Group, a media house currently led by Flaka Surroi.
Roads in Kosovo The R 6 Motorway ( Albanian : Autostrada R 6 ; Serbian : Autoput R 6 ), also commonly Autostrada Prishtinë-Han i Elezit and Autostrada Prishtinë-Shkup or Autostrada Arbën Xhaferi , is a motorway in Kosovo running 60 kilometres (37 mi) in the districts of Ferizaj and Pristina . [ 1 ]
Etrolizumab was developed by Genentech [2] [3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells. [4] As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.
The combination increased progression-free survival to an average of 12.3 months, compared to 7.2 months for vemurafenib alone. This clinical data also showed that the combination treatment resulted in 65% survival rate of participants 17 months after beginning the treatment, increased rates from the 50% of participants on vemurafenib treatment ...